T cell therapies for multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests new antibody treatments for multiple myeloma, given alone or with other drugs. It aims to see if they can control the disease and what side effects might occur.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that is either newly diagnosed or has come back or stopped responding to treatment.
- You are able to take care of most daily tasks yourself (ECOG score 0 or 1).
- You do not have multiple myeloma that has spread to your brain or spinal cord.
- You do not have an active infection at the start of the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs—etentamig given through a vein and a CELMoD pill—for people whose multiple myeloma has come back or stopped responding to treatment. The goal is to see if this combination is safe and helps control the disease.
This trial tests a type of immune therapy called bispecific T-cell redirectors combined with standard medicines for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if this treatment helps control the cancer better.
This is an early (Phase 1) study focused on safety of an IV medicine called etentamig in adults with relapsed or refractory multiple myeloma. It looks at how the treatment affects side effects and helps decide the safest way to give it.
This trial is testing a new combination of drugs for people with untreated multiple myeloma who are healthy enough for a stem cell transplant. It aims to see if the treatment is safe and effective.
This trial tests a new CAR-T cell therapy (called arlocabtagene autoleucel) combined with other drugs for multiple myeloma that has returned or stopped responding. It aims to find a safe and effective dose while tracking how well the treatment works.
This trial tests a combination of three drugs (CM336, daratumumab, and lenalidomide) for people with newly diagnosed multiple myeloma who are not eligible for a stem cell transplant. The goal is to see if this combination is safe and effective in controlling the disease.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.